Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.63 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.44 |
| ▸ | ITGAL | P20701 | 2/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473104 | 1.00 | ECE1 (0.63) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL30910815 | 1.00 | ECE1 (0.63) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL11517272 | 1.00 | ECE1 (0.63) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL5582285 | 1.00 | ECE1 (0.63) | ECE1NOD1ITGB2ICAM1ITGAL | |
| D-Alanine SCHEMBL9140010 | 0.98 | ECE1 (0.61) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL31390152 | 0.96 | ECE1 (0.59) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL20789058 | 0.93 | ECE1 (0.56) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL31026346 | 0.93 | ECE1 (0.56) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL20263697 | 0.93 | ECE1 (0.56) | ECE1NOD1ITGB2ICAM1ITGAL | |
| SCHEMBL31026345 | 0.93 | ECE1 (0.56) | ECE1NOD1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122028936-A | Antibody-drug conjugates | ADC疗法责任有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4735021-A1 | COMBINATION THERAPY | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| EP-4731239-A1 | ANALOGUES WITH IMPROVED PROPERTIES | Zealand Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | claimed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | claimed |
| CN-114450293-A | Anthracycline derivatives | 阿尔麦克探索有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| WO-2022058395-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2022-03-24 | — | — | WO | claimed |
| EP-0357784-B1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-09-02 | — | — | EP | claimed |
| EP-0357784-A1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES. | KYOWA HAKKO KOGYO KK (JP) | 1990-03-14 | — | — | EP | claimed |
| WO-1989006497-A1 | A FEED COMPOSITION FOR CULTURING FISHES AND SHELLFISHES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | ECE1 2478/4885NOD1 2061/4885ITGB2 362/4885 |
| US-11382956-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | ECE1 584/4885NOD1 666/4885ITGB2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.